Blockchain Registration Transaction Record

Newron Pharmaceuticals Elects New Board Members at AGM 2026

Newron Pharmaceuticals AGM 2026 approves election of new board members George Garibaldi and Paolo Zocchi. Lead candidate evenamide advances in Phase III for treatment-resistant schizophrenia.

This news matters because Newron's progress in developing evenamide for treatment-resistant schizophrenia could address a significant unmet medical need. With clinical data showing sustained efficacy and safety, the drug has the potential to improve outcomes for patients who do not respond to existing antipsychotics. The board refreshment injects fresh expertise, while ongoing partnerships expand global reach. Investors and patients alike should watch for ENIGMA-TRS Phase III results, which could reshape schizophrenia treatment.